Rituximab for myasthenia gravis (Protocol)

<strong>Objectives</strong> <p>This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess:</p> <p>• the safety and eGicacy, as assessed by the eGect on disease severity or functional ability and the burden of alternative treatment, of rituximab (including biosimilar variants) for the treatment of myasthenia gravis in adults; and • outcomes and adverse eGects between diGerent patient subgroups, and treatment strategies, in order to aid treatment choice for individuals, and to inform policymakers about those most likely to benefit.</p>